997 results on '"Sonke, Gabe S."'
Search Results
2. Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
3. Moderators of exercise effects on self-reported cognitive functioning in cancer survivors: an individual participant data meta-analysis
4. Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer
5. Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)
6. Correction: Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer
7. The tyranny of non-inferiority trials
8. Dose selection of novel anticancer drugs: exposing the gap between selected and required doses
9. EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe
10. Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned
11. Predicting treatment outcome using kinome activity profiling in HER2+ breast cancer biopsies
12. High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
13. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer
14. Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels
15. Immune landscape of breast tumors with low and intermediate estrogen receptor expression
16. MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
17. Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications
18. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
19. Tumour-educated platelets for breast cancer detection: biological and technical insights
20. PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial
21. A review on genetic alterations in CNS metastases related to breast cancer treatment. Is there a role for liquid biopsies in CSF?
22. Is there a Role for Hyperthermic Intraperitoneal Chemotherapy in Front-line Therapy for Ovarian Cancer?
23. Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.
24. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer
25. Is routine admission to a critical care setting following hyperthermic intraperitoneal chemotherapy for ovarian cancer necessary?
26. Health state utility and health-related quality of life measures in patients with advanced ovarian cancer
27. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
28. Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study)
29. Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2+ breast cancer
30. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial
31. Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors
32. Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
33. Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (OVHIPEC-2)
34. A Bayesian-adaptive decision-theoretic approach can reduce the sample sizes for multiarm exercise oncology trials
35. On-treatment (tx) dynamic circulating tumor DNA changes (∆ctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA-3 (ML-3).
36. Cognitive function in patients with HR+ advanced breast cancer treated with endocrine therapy with or without CDK4/6 inhibitors in the SONIA trial.
37. Oncologic outcome of response-guided axillary treatment in patients with cN1 breast cancer after primary systemic therapy.
38. Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights
39. Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era
40. Local and systemic therapy in breast cancer patients with central nervous system metastases
41. Solitary ovarian cancer cells in the peritoneum: What happens below the surface?
42. Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluation
43. The Effects of Being Informed About Chemotherapy-Related Cognitive Symptoms With And Without Self-Affirmation on Perceived Cognitive Symptoms of Breast Cancer Patients: A Randomized Prospective, Longitudinal Study
44. Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors: A Cross-Sectional Study
45. Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol
46. Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers
47. Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance
48. Socioeconomic status and its relation with breast cancer recurrence and survival in young women in the Netherlands
49. High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer.
50. Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.